Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6839921 in Advanced Malignancies and AML
NCT02098967Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2014
- Primary completion
- May 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of RO6839921 in solid tumor and acute myeloid leukemia (AML) (3 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events at 1 year and Incidence of dose-limiting toxicities at 1 year. Started Apr 2014; status: completed.
02
Drugs
RO6839921
03
Conditions
solid tumoracute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02098967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098967.